Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02-Reference-Cited by-同舟云学术

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Published:2013-03-14 Issue:11 Volume:121 Page:1968-1975
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Leleu Xavier¹,Attal Michel²,Arnulf Bertrand³,Moreau Philippe⁴,Traulle Catherine⁵,Marit Gerald⁶,Mathiot Claire⁷,Petillon Marie Odile¹,Macro Margaret⁸,Roussel Murielle²,Pegourie Brigitte⁹,Kolb Brigitte¹⁰,Stoppa Anne Marie¹¹,Hennache Bernadette¹,Bréchignac Sabine¹²,Meuleman Nathalie¹³,Thielemans Beatrice¹,Garderet Laurent¹⁴,Royer Bruno¹⁵,Hulin Cyrille¹⁶,Benboubker Lotfi¹⁷,Decaux Olivier¹⁸,Escoffre-Barbe Martine¹⁸,Michallet Mauricette¹⁹,Caillot Denis²⁰,Fermand Jean Paul³,Avet-Loiseau Hervé³,Facon Thierry¹

Affiliation:

1. Hôpital Huriez, CHRU, Lille, France;

2. Hôpital Purpan, Toulouse, France;

3. Saint Louis, APHP, Paris, France;

4. Hotel Dieu, Nantes, France;

5. Centres Hospitaliers Lyon Sud et Edouard Herriot, Lyon, France;

6. Hôpital du Haut-Lévèque, Bordeaux Pessac, France;

7. Institut Curie, Paris, France;

8. Hôpital Côte de Nacre, Caen, France;

9. Hôpital A. Michallon, Grenoble, France;

10. Hôpital Robert Debré, Reims, France;

11. Institut Paoli Calmettes, Marseille, France;

12. Bobigny-Avicennes, APHP, Paris, France;

13. Institute Jules Bordet, ULB, Brussels, Belgium;

14. Saint Antoine, APHP, Paris, France;

15. Hôpital Sud, Amiens, France;

16. Hôpital de Brabois, Nancy-Brabois, Vandoeuvre, France;

17. Hôpital Bretonneau, Tours, France;

18. Hôpital Sud, Rennes, France;

19. Hôpital Edouard Herriot, Lyon, France; and

20. Hôpital d’Enfants, Dijon, France

Abstract

Key Points Combination of pomalidomide with dexamethasone is highly active and can salvage end stage myeloma refractory to lenalidomide and bortezomib. Current data suggest pomalidomide 4 mg/day on days 1 to 21 per 28-days cycle with dexmethasone should be studied in future phase 3 trials.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/11/1968/1364148/1968.pdf

Reference16 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies.;Kumar;Blood,2008

2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study.;Kumar;Leukemia,2012

3. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.;Schey;J Clin Oncol,2004

4. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.;Streetly;Br J Haematol,2008

5. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.;Lacy;J Clin Oncol,2009

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment;Clinical Lymphoma Myeloma and Leukemia;2023-11

2. Помалидомид в терапии рецидивирующей/рефрактерной множественной миеломы;Journal of Modern Oncology;2023-08-10

3. GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c‐MET tyrosine kinase;Cancer Medicine;2023-02-24

4. Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis;Therapeutic Advances in Hematology;2023-01

5. Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma;Cancers;2022-12-16